Intellia Therapeutics, INC. 8-K Filing
Ticker: NTLA · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1652130
Sentiment: neutral
Filing Stats: 2,493 words · 10 min read · ~8 pages · Grade level 14.9 · Accepted 2025-11-10 17:24:38
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
Filing Documents
- d12611d8k.htm (8-K) — 44KB
- d12611dex991.htm (EX-99.1) — 23KB
- d12611dex992.htm (EX-99.2) — 24KB
- g12611g1111003715793.jpg (GRAPHIC) — 7KB
- 0001193125-25-274596.txt ( ) — 233KB
- ntla-20251108.xsd (EX-101.SCH) — 3KB
- ntla-20251108_lab.xml (EX-101.LAB) — 18KB
- ntla-20251108_pre.xml (EX-101.PRE) — 11KB
- d12611d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding: the safety, tolerability, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or "lonvo-z" (f/k/a NTLA-2002) for hereditary angioedema ("HAE") and nexiguran ziclumeran or "nex-z" (f/k/a NTLA-2001) for transthyretin ("ATTR") amyloidosis, including the ability to successfully complete its global Phase 3 HAELO study of lonvo-z for HAE and to address the clinical hold that the United States Food and Drug Administration ("FDA") placed on the investigational new drug ("IND") applications for its global Phase 3 MAGNITUDE study of nex-z for ATTR amyloidosis with cardiomyopathy ("ATTR-CM") and its global Phase 3 MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy ("ATTRv-PN") to resume the MAGNITUDE and MAGNITUDE-2 clinical trials; its ability to present a topline data readout from the HAELO study by mid-2026; lonvo-z's potential to become a one-time treatment for HAE; and nex-z's potential to become a one-time treatment for ATTR amyloidosis. Any forward-looking statements in this current report on Form 8-K are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: November 10, 2025 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President